Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

Autor: Zurko J; University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI., Ramdial J; The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation, Division of Cancer Medicine, Houston, TX., Shadman M; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA., Ahmed S; The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation, Division of Cancer Medicine, Houston, TX., Szabo A; University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI., Iovino L; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA., Tomas AA; Memorial Sloan Kettering Cancer Center, New York, NY., Sauter C; Memorial Sloan Kettering Cancer Center, New York, NY., Perales MA; Memorial Sloan Kettering Cancer Center, New York, NY., Shah NN; University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI., Acharya UH; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA., Jacobson C; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA., Soiffer RJ; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA., Wang T; Sylvester Comprehensive Cancer Center, Division of Transplantation and Cellular Therapy, Miami, FL., Komanduri KV; Sylvester Comprehensive Cancer Center, Division of Transplantation and Cellular Therapy, Miami, FL., Jaglowski S; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH., Kittai AS; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH., Denlinger N; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH., Iqbal M; Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Jacksonville, FL., Kharfan-Dabaja MA; Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Jacksonville, FL., Ayala E; Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Jacksonville, FL., Chavez J; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Jain M; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Locke FL; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Samara Y; City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA., Budde LE; City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA., Mei MG; City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA., Pia AD; John Theurer Cancer Center at Hackensack Meridian Health, NJ, USA; Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ., Feldman T; John Theurer Cancer Center at Hackensack Meridian Health, NJ., Ahmed N; University of Kansas Medical Center, Division of Hematologic Malignancies and Cellular Therapeutics, Westwood, KS., Jacobs R; Levine Cancer Institute/Atrium Health, Charlotte, NC., Ghosh N; Levine Cancer Institute/Atrium Health, Charlotte, NC., Dholaria B; Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Nashville, TN., Oluwole OO; Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Nashville, TN., Hess B; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC., Hassan A; University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI., Kenkre VP; University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI., Reagan P; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Awan F; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX., Nieto Y; The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation, Division of Cancer Medicine, Houston, TX., Hamadani M; Medical College of Wisconsin, BMT and Cellular Therapy Program, Division of Hematology and Oncology, Milwaukee, WI., Herrera AF; City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA. aherrera@coh.org.

Publikováno v: Haematologica [Haematologica] 2023 Jan 01; Vol. 108 (1), pp. 98-109. Date of Electronic Publication: 2023 Jan 01.

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML).

Autor: Acharya UH; Divisions of Hematologic Malignancies & Immune Effector Cell Therapy, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02215, USA., Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA 98195, USA.; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA 98195, USA.; Department of Epidemiology, University of Washington, Seattle, WA 98195, USA.

Publikováno v: Cancers [Cancers (Basel)] 2020 Dec 03; Vol. 12 (12). Date of Electronic Publication: 2020 Dec 03.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Autor: Chow VA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Gopal AK; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Turtle CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Smith SD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Ujjani CS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington., Till BG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Tseng YD; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Radiation Oncology, University of Washington, Seattle, Washington., Warren EH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Shustov AR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington., Menon MP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington., Bhark S; Seattle Cancer Care Alliance, Seattle, Washington.; Fred Hutchinson Cancer Research Center, Public Health Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Acharya UH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.; Department of Medical Oncology, Divisions of Hematologic Malignancies and Cellular Therapy, Dana Farber Cancer Institute, Boston, Massachusetts., Mullane E; Seattle Cancer Care Alliance, Seattle, Washington., Hannan LM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Voutsinas JM; Swedish Cancer Institute, Seattle, Washington., Gooley TA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Swedish Cancer Institute, Seattle, Washington., Lynch RC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Cancer Care Alliance, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.

Publikováno v: American journal of hematology [Am J Hematol] 2019 Aug; Vol. 94 (8), pp. E209-E213. Date of Electronic Publication: 2019 May 21.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Autor: Hay KA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Hirayama AV; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Voutsinas JM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Wu Q; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Li D; Juno Therapeutics, Seattle, WA; and., Gooley TA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Cherian S; Department of Laboratory Medicine and., Chen X; Department of Laboratory Medicine and., Pender BS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Hawkins RM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Vakil A; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Steinmetz RN; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Schoch G; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Chapuis AG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Till BG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Kiem HP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Ramos JD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Acharya UH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Turtle CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA.

Publikováno v: Blood [Blood] 2019 Apr 11; Vol. 133 (15), pp. 1652-1663. Date of Electronic Publication: 2019 Feb 06.